AB-836
Based on 1 Customer Validation
AB-836 is an orally active HBV capsid inhibitor. AB-836 inhibits viral replication by interacting with HBV core protein. AB-836 can be used in research related to chronic hepatitis B.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.13%
- No. CAS: 2445597-31-7
- Fòrmula: C20H15F3N4O2
- Peso molecular:400.35
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Orally Active Compound Library
HY-L061
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Infection Compound Library
HY-L002
-
Antiviral Compound Library
HY-L027
Actividad biológica
AB-836 (0.0001-10 μM; 6 days) potently inhibits HBV replication in HepDE19 cells with an EC50 of 0.010 μM, acting by blocking pgRNA encapsidation without reducing viral transcript or core protein levels, and its activity is modestly reduced (3-fold) in the presence of 40% human serum[2].
AB-836 inhibits multiple markers of HBV de novo infection, including HBV DNA, pgRNA, HBV RNA, HBsAg, HBeAg, and cccDNA, with EC50 values ranging from 0.002 to 0.52 μM in PHHs and HepG2-NTCP cells[2].
AB-836 (3 days) exhibits broad coverage of HBV genotypes A to H, remains fully active against nucleos(t)ide analog-resistant HBV variants, and demonstrates activity against most core protein variants, with EC50 values ranging from 0.004 to 0.78 μM across tested variants[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD.CB17-Prkdcscid/J mice[2]
-
Dosage:3 mg/kg; 10 mg/kg
-
Administration:p.o.; once daily; 7 days
-
Result:Inhibited HBV replication in HBV hydrodynamic injection mice, with the 10 mg/kg once-daily dose reducing mean serum and liver HBV DNA by 2.51 log10 and 1.45 log10, respectively
Chemical Information
-
No. CAS 2445597-31-7
-
Appearance Solid
-
Peso molecular 400.35
-
Fòrmula C20H15F3N4O2
-
Color White to off-white
-
SMILES
FC1=C(C#N)C=C(NC(N(C)[C@H](C)C2=CNC(C3=C2C=C(F)C(F)=C3)=O)=O)C=C1
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
DMSO : 100 mg/mL (249.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureza y Documentación
-
Ficha de datos (273 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Degasperi E, et al. Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies. Viruses. 2022;14(11):2404. Published 2022 Oct 29. [Content Brief]
[2]. Lam AM, et al. Preclinical and clinical antiviral characterization of AB-836, a potent capsid assembly modulator against hepatitis B virus. Antiviral Res. 2024;231:106010. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4978 mL | 12.4891 mL | 24.9781 mL | 62.4454 mL |
| 5 mM | 0.4996 mL | 2.4978 mL | 4.9956 mL | 12.4891 mL | |
| 10 mM | 0.2498 mL | 1.2489 mL | 2.4978 mL | 6.2445 mL | |
| 15 mM | 0.1665 mL | 0.8326 mL | 1.6652 mL | 4.1630 mL | |
| 20 mM | 0.1249 mL | 0.6245 mL | 1.2489 mL | 3.1223 mL | |
| 25 mM | 0.0999 mL | 0.4996 mL | 0.9991 mL | 2.4978 mL | |
| 30 mM | 0.0833 mL | 0.4163 mL | 0.8326 mL | 2.0815 mL | |
| 40 mM | 0.0624 mL | 0.3122 mL | 0.6245 mL | 1.5611 mL | |
| 50 mM | 0.0500 mL | 0.2498 mL | 0.4996 mL | 1.2489 mL | |
| 60 mM | 0.0416 mL | 0.2082 mL | 0.4163 mL | 1.0408 mL | |
| 80 mM | 0.0312 mL | 0.1561 mL | 0.3122 mL | 0.7806 mL | |
| 100 mM | 0.0250 mL | 0.1249 mL | 0.2498 mL | 0.6245 mL |
AB-836 Related Classifications
HY-148348 Related Classifications
Powered by Bioz